Early intravenous beta blockade and thrombolytics in acute myocardial infarction.
This article discusses therapy with beta blockade and thrombolytic agents in acute myocardial infarction. In large and well-controlled studies both treatment strategies have been shown to increase survival. Both therapies have also been demonstrated to be safe in acute myocardial infarction. Historically, the 2 different treatment strategies have been tested during different time periods, resulting in few studies with the main objective to study the combined effects of the 2 agents. From the data that are presently available, however, there is a clear suggestion of additive beneficial effect and the 2 treatments given in combination are well tolerated.
Olsson
G
G
Cardiovascular Medicine, Astra Hässle AB, Mölndal, Sweden.
Held
P
P
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy*; D016019:Survival Analysis; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D005343:Fibrinolytic Agents